tamoxifen

Our newest treatment guideline on the use of low-dose Tamoxifen in ER+ DCIS – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared on X:

“Check out our newest treatment guideline on the use of low-dose tamoxifen in patients with estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS).”

Additional information.
Source: Dana-Farber’s Breast Oncology Center/X

cancer Dana-Farber’s Breast Oncology Center DCIS ductal carcinoma in situ Estrogen OncoDaily Oncology tamoxifen